Chemist Emily Mevers and her team recently discovered a new set of complex structures in millipede secretions that can ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Recent discoveries of how the brain works have shifted focus to brain networks, offering potential new hope for people ...

Precision-targeted therapy via antibody drugs has become central to the field of cancer immunotherapy. Monoclonal antibodies ...

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

The company’s common stock is expected to begin trading on a split-adjusted basis when the markets open on July 28, 2025 under the company’s existing ticker “MRSN” with the new CUSIP number 59045L 205 ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

Using patient-derived B cells, Kling-Select facilitates the rapid detection of new antibodies and preserved viral epitopes.

A new study published in Nanotechnology offers new hope for less harmful breast cancer therapy by combining two powerful, non ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...